Namsco Corp Ordinary Shares NAMS 深 滬
等待開盤 10-21 09:30:00 美东时间
37.66
+1.260
+3.46%
華盛通- 最 高38.1325
- 今 開36.59
- 成交量 142.90万股
- 最 低 36.12
- 昨 收 36.40
- 總市值 42.56亿
- 52周最高 41.47
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 14.06
- 委 比 -4.38%
- 總股本 1.13亿
- 歷史最高 41.47
- 量 比 0.66
- 振 幅 5.53%
- 歷史最低 5.6326
- 每 手 1
- 風險率 4.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
Across the recent three months, 4 analysts have shared their insights on NewAms...
10-20 20:03
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North
10-16 20:47
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NewAmsterdam Pharma announced that its Chief Scientific Officer, John Kastelein, and Executive Vice President, Matthew Philippe, will participate in a virtual fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 11:00 a.m. ET. The session will be webcast live on the company’s investor relations website, with an archived replay available afterward. NewAmsterdam is a biopharmaceutical company focused on developin...
09-24 12:00
Wells Fargo Initiates Coverage On NewAmsterdam Pharma Co with Overweight Rating, Announces Price Target of $45
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announces Price Target of $45.
08-25 19:27
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
The European Medicines Agency (EMA) has validated the Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and the obicetrapib plus ezetimibe fixed-dose combination (FDC) for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. NewAmsterdam Pharma, in partnership with Menarini, has submitted these applications, with Menarini responsible for regulatory communications and commercialization in Europe. T...
08-18 12:00
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $39
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $38 to $39.
08-07 23:07
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of $(0.41) per share
08-07 05:51
NewAmsterdam Pharma reports Q2 results
NewAmsterdam Pharma press release (NASDAQ:NAMS): Q2 net loss of $17.47M Revenue of $19.15M (+739.9% Y/Y). More on NewAmsterdam Pharma Seeking Alpha’s Quant Rating on NewAmsterdam Pharma Historical ear...
08-06 19:47
'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News
https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
07-30 20:25
